Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JANX NASDAQ:KRYS NASDAQ:MRUS NASDAQ:MTSR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$23.70-3.0%$23.99$21.73▼$71.71$1.42B2.84904,879 shs813,825 shsKRYSKrystal Biotech$179.61+1.7%$150.56$122.80▼$207.84$5.20B0.66333,161 shs534,525 shsMRUSMerus$94.15$67.77$33.19▼$94.56$7.12B1.191.13 million shs6.71 million shsMTSRMetsera$52.12-0.4%$36.95$12.30▼$54.47$5.48BN/A1.32 million shs2.34 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics+3.12%+6.35%+7.57%+1.58%-46.20%KRYSKrystal Biotech-0.12%+7.01%+19.52%+24.89%-3.02%MRUSMerus+0.51%+38.01%+43.00%+76.54%+88.45%MTSRMetsera+0.44%-1.26%+48.29%+81.32%+5,232,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$23.70-3.0%$23.99$21.73▼$71.71$1.42B2.84904,879 shs813,825 shsKRYSKrystal Biotech$179.61+1.7%$150.56$122.80▼$207.84$5.20B0.66333,161 shs534,525 shsMRUSMerus$94.15$67.77$33.19▼$94.56$7.12B1.191.13 million shs6.71 million shsMTSRMetsera$52.12-0.4%$36.95$12.30▼$54.47$5.48BN/A1.32 million shs2.34 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics+3.12%+6.35%+7.57%+1.58%-46.20%KRYSKrystal Biotech-0.12%+7.01%+19.52%+24.89%-3.02%MRUSMerus+0.51%+38.01%+43.00%+76.54%+88.45%MTSRMetsera+0.44%-1.26%+48.29%+81.32%+5,232,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJANXJanux Therapeutics 3.06Buy$78.31230.41% UpsideKRYSKrystal Biotech 2.86Moderate Buy$209.0016.36% UpsideMRUSMerus 2.25Hold$92.88-1.35% DownsideMTSRMetsera 2.57Moderate Buy$55.756.96% UpsideCurrent Analyst Ratings BreakdownLatest JANX, MTSR, MRUS, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.009/30/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold9/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.009/30/2025MRUSMerusLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$97.009/30/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$54.009/29/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$135.00 ➝ $97.009/29/2025MRUSMerusCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$67.00 ➝ $97.009/29/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/29/2025MRUSMerusTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$88.00 ➝ $97.00(Data available from 10/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJANXJanux Therapeutics$10.59M134.48N/AN/A$19.49 per share1.22KRYSKrystal Biotech$359.21M14.47$4.71 per share38.11$32.90 per share5.46MRUSMerus$36.13M197.08N/AN/A$9.46 per share9.95MTSRMetseraN/AN/AN/AN/A($2.46) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9236.5117.82N/A40.85%15.21%13.81%11/3/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/ALatest JANX, MTSR, MRUS, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 million7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJANXJanux TherapeuticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJANXJanux TherapeuticsN/A47.0347.03KRYSKrystal BiotechN/A9.689.33MRUSMerusN/A8.398.39MTSRMetseraN/A5.265.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJANXJanux Therapeutics75.39%KRYSKrystal Biotech86.29%MRUSMerus96.14%MTSRMetseraN/AInsider OwnershipCompanyInsider OwnershipJANXJanux Therapeutics29.40%KRYSKrystal Biotech13.70%MRUSMerus3.70%MTSRMetseraN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableMTSRMetsera81105.06 millionN/AN/AJANX, MTSR, MRUS, and KRYS HeadlinesRecent News About These CompaniesMetsera (NASDAQ:MTSR) Upgraded by Wall Street Zen to "Hold" RatingOctober 1 at 3:19 AM | americanbankingnews.comMetsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street ZenOctober 1 at 3:17 AM | marketbeat.comHealthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drugSeptember 30 at 3:39 PM | cnbc.comPfizer licking its lips as Metsera presents positive weight loss dataSeptember 30 at 12:45 PM | thepharmaletter.comTMetsera (NASDAQ:MTSR) Cut to Equal Weight at Wells Fargo & CompanySeptember 30 at 8:50 AM | marketbeat.comMetsera downgraded to Equal Weight from Overweight at Wells FargoSeptember 29 at 9:43 PM | msn.comMetsera's obesity drug shows promising weight loss in mid-stage trialsSeptember 29 at 4:11 PM | reuters.comMetsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3September 29 at 4:01 PM | globenewswire.comMetsera (MTSR): Rethinking Valuation After a Quiet 49% RallySeptember 27, 2025 | finance.yahoo.comMetsera (NASDAQ:MTSR) Cut to "Hold" at Leerink PartnrsSeptember 27, 2025 | americanbankingnews.comMetsera Inc. (NASDAQ:MTSR) Receives $63.50 Average PT from AnalystsSeptember 27, 2025 | americanbankingnews.comPfizer is Locking in New Growth Through a New Acquisition (MTSR)...September 26, 2025 | marketbeat.comGoldman Sachs Group Inc. Buys Shares of 20,856 Metsera Inc. $MTSRSeptember 26, 2025 | marketbeat.comLeerink Partners Downgrades Metsera (MTSR)September 26, 2025 | msn.comMetsera (NASDAQ:MTSR) Receives "Market Perform" Rating from Leerink PartnersSeptember 26, 2025 | americanbankingnews.comMetsera downgraded to Market Perform from Outperform at LeerinkSeptember 25, 2025 | finance.yahoo.comMetsera (NASDAQ:MTSR) Lowered to Hold Rating by Leerink PartnrsSeptember 25, 2025 | marketbeat.comMetsera (NASDAQ:MTSR) Earns Market Perform Rating from Leerink PartnersSeptember 24, 2025 | marketbeat.comRhumbline Advisers Invests $520,000 in Metsera Inc. $MTSRSeptember 24, 2025 | marketbeat.comMetsera Inc. (NASDAQ:MTSR) Receives Consensus Rating of "Buy" from AnalystsSeptember 24, 2025 | marketbeat.comTime to Buy Pfizer (PFE) or Metsera (MTSR) Stock?September 23, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJANX, MTSR, MRUS, and KRYS Company DescriptionsJanux Therapeutics NASDAQ:JANX$23.70 -0.74 (-3.03%) Closing price 04:00 PM EasternExtended Trading$23.68 -0.02 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Krystal Biotech NASDAQ:KRYS$179.61 +3.08 (+1.74%) Closing price 04:00 PM EasternExtended Trading$179.76 +0.15 (+0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Merus NASDAQ:MRUS$94.15 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$94.14 -0.01 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Metsera NASDAQ:MTSR$52.12 -0.21 (-0.40%) As of 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Eyes New Highs, Boosted by Boeing Partnership Is Draganfly's Army Partnership a Game-Changer for Investors? Is Tilray's Stock Price Surge a Pipe Dream of Political Hype? Lamb Weston: Is the King of Spuds a Buy or a Dud for 2026? Lithium Americas Stock Exploded Last Week—Here’s Why Is Intuitive Surgical the Hidden Winner in Healthcare’s Weakness? Marvell Soars on +$6B in Buybacks—Can the Recovery Continue? 154% Jump in Bullish Bets: Is Ford About to Hit the Gas? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
